91制片厂 and Max Planck Team Up on First Joint Position
From left: Jeff Atwater, 91制片厂鈥檚 vice president for strategic initiatives and CFO; Matthias Haury, Ph.D., MPFI鈥檚 COO; Ken-Dawson-Scully, Ph.D., associate vice president for strategic initiatives and head of institutional partnerships at 91制片厂 and MPFI; 91制片厂 President John Kelly; and David Fitzpatrick, Ph.D., CEO and scientific director of MPFI.
and (MPFI) have combined forces to form the first jointly supported position between the two institutions. As of May 1, , Ph.D., will be newly appointed to the role of associate vice president for strategic initiatives and head of institutional partnerships for 91制片厂 and MPFI. Joining 91制片厂 in 2008, Dawson-Scully served as associate director of the 91制片厂 and most recently as an associate professor of and associate dean for graduate studies in 91制片厂鈥檚 .
鈥淔or almost a decade, the close and synergistic partnership between 91制片厂 and Max Planck Florida Institute for Neuroscience has been undeniably beneficial for our institutions and Palm Beach County,鈥 said 91制片厂 President . 鈥淭his latest initiative will foster tremendous returns on our co-investment for educational and research opportunities, economic development, as well as faculty and student recruitment. Together, we will continue to strengthen our thriving alliance; enhancing recognition and visibility both locally and globally.鈥
In this joint 91制片厂/MPFI position, Dawson-Scully will work closely with the executive leadership team of both institutions under the direction of , Ph.D., MPFI鈥檚 COO and , 91制片厂鈥檚 vice president for strategic initiatives and CFO.
鈥淲e are excited to further reinforce the flourishing relationship with our partners at 91制片厂. Our joint efforts will continue to facilitate unique collaborative opportunities between our institutions and inspire a vibrant, creative space where groundbreaking innovations in science and technology will prosper,鈥 said , Ph.D., CEO and scientific director of MPFI. 鈥淭his collaborative environment will allow us the opportunity to better tackle the areas of focus that are critical to the success of both of our institutions鈥 missions, goals and aspirations.鈥
In his new role, Dawson-Scully will be responsible for developing and implementing key initiatives in areas that are crucial to 91制片厂 and MPFI. These initiatives will include co-branding programs, enhancing infrastructure, developing new educational programs, identifying and securing joint funding opportunities, conducting research training, building partnerships, and fostering collaboration between academic and administrative units.
Additionally, as the head of this new initiative, Dawson-Scully will act as a liaison for both institutes, developing and sustaining strong relationships with local and international foundations, corporations, government and community groups.
鈥淚 am both honored and excited to serve in this new capacity for Max Planck Florida Institute for Neuroscience and 91制片厂. My ultimate goal is to escalate our international reputation and expand our distinguished faculty, recruiting talented students and world-class scientists to our institutions,鈥 said Dawson-Scully. 鈥淏y combining our expertise, knowledge and resources, our close partnership will generate significant impact, benefitting the local, regional and international communities.鈥
The most recent joint program, where 91制片厂 and MPFI have partnered, is the 91制片厂 Max Planck Honors Program. The 91制片厂 MPHP is an elite undergraduate program that can be accomplished as an undergraduate student, in either 91制片厂鈥檚 or the College of Science, focused on the . Applications for the first cohort for this fall are due April 30, and more information for the 91制片厂 MPHP can be found at .
Dawson-Scully received his Ph.D. from the University of Toronto in 2003, and his M.Sc. from Queen鈥檚 University in 1998. He currently serves on the steering committee and is a faculty member of the newly formed International Max Planck Research School (IMPRS). A highly accomplished researcher, his work investigates ways to protect the brain from neurodegeneration caused by acute or chronic cellular stress using the genetic model organism, the fruit fly or D. melanogaster. Dawson-Scully has identified a number of molecular targets in the fruit fly nervous system that can rescue the damaging effects of pathological conditions such as high temperature, low oxygen, and oxidative stress. This impactful research opens up new avenues for the future treatment of human diseases such as stroke and epilepsy. His findings, which have been successfully translated from fly, to zebrafish, fresh water turtle, and mouse, have led to the submissions of four novel United States patents for the medical treatment of febrile seizure, migraine, and stroke in humans. Dawson-Scully also serves as the chief scientific officer for Neuro Pharmalogics, Inc., an 91制片厂 Tech Runway庐 start-up company that has licensed his intellectual property for the purpose of creating novel therapeutics aimed at combating brain related diseases.-91制片厂-